Abstract: Age-specific probiotic–drug hybrid formulations represent an emerging class of therapeutics that combine live microorganisms with pharmaceutical agents to enhance clinical efficacy, minimize adverse effects, and maintain gut microbiome homeostasis across different age groups. Despite their potential, these hybrids face significant regulatory challenges due to their dual identity as both biologics and drugs, creating ambiguity in classification, evaluation, and approval. Global regulatory agencies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO), lack harmonized guidelines for such formulations, resulting in fragmented standards and delayed market entry. This study provides a comprehensive review of existing regulatory frameworks to identify gaps in safety assessment, clinical validation, manufacturing, and postmarket surveillance of probiotic–drug hybrids. A comparative decision matrix is developed to map and contrast the FDA, EMA, and CDSCO approval pathways, highlighting differences in evidentiary and procedural requirements. Building on this analysis, an age-stratified regulatory roadmap is proposed to account for physiological, metabolic, and microbiome-related variations among pediatric, adult, and geriatric populations. The roadmap emphasizes adaptive trial designs, long-term safety monitoring, and age-appropriate dosage and labeling requirements. By integrating scientific, clinical, and regulatory perspectives, this paper provides a structured foundation for harmonizing international approval processes and guiding future policy development. The findings aim to support regulatory convergence, enhance safety assurance, and facilitate the ethical and efficient advancement of probiotic–drug hybrid formulations in global healthcare.
Nayan et al. (Wed,) studied this question.